Jpmorgan Chase & CO Eliem Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 291,796 shares of ELYM stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
291,796
Previous 12,776
2183.94%
Holding current value
$1.2 Million
Previous $65,000
1744.62%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ELYM
# of Institutions
77Shares Held
53.4MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.09% of portfolio
-
Janus Henderson Group PLC London, X03.18MShares$13.1 Million0.01% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.61MShares$10.7 Million3.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.51MShares$6.19 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.04MShares$4.27 Million0.19% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...